Annovis Bio Stock Current Valuation
| ANVS Stock | USD 6.54 0.02 0.30% |
Valuation analysis of Annovis Bio helps investors to measure Annovis Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to gain to -3.95 in 2024. Enterprise Value Multiple is likely to gain to -3.95 in 2024. Fundamental drivers impacting Annovis Bio's valuation include:
Price Book 12.8134 | Enterprise Value 77.9 M | Enterprise Value Ebitda (3.57) |
Undervalued
Today
Please note that Annovis Bio's price fluctuation is somewhat reliable at this time. Calculation of the real value of Annovis Bio is based on 3 months time horizon. Increasing Annovis Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Annovis stock is determined by what a typical buyer is willing to pay for full or partial control of Annovis Bio. Since Annovis Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Annovis Stock. However, Annovis Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.54 | Real 16.16 | Target 46.0 | Hype 6.5 | Naive 7.29 |
The intrinsic value of Annovis Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Annovis Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Annovis Bio helps investors to forecast how Annovis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Annovis Bio more accurately as focusing exclusively on Annovis Bio's fundamentals will not take into account other important factors: Annovis Bio Company Current Valuation Analysis
Annovis Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Annovis Bio Current Valuation | 77.87 M |
Most of Annovis Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annovis Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Annovis Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Annovis Bio is extremely important. It helps to project a fair market value of Annovis Stock properly, considering its historical fundamentals such as Current Valuation. Since Annovis Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Annovis Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Annovis Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Annovis Current Valuation Historical Pattern
Today, most investors in Annovis Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Annovis Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Annovis Bio current valuation as a starting point in their analysis.
Annovis Bio Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Annovis Bio has a Current Valuation of 77.87 M. This is 99.46% lower than that of the Biotechnology sector and 98.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.53% higher than that of the company.
Annovis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Annovis Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Annovis Bio could also be used in its relative valuation, which is a method of valuing Annovis Bio by comparing valuation metrics of similar companies.Annovis Bio is currently under evaluation in current valuation category among its peers.
Annovis Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Annovis Bio from analyzing Annovis Bio's financial statements. These drivers represent accounts that assess Annovis Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Annovis Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 43.2M | 47.6M | 134.1M | 109.6M | 98.7M | 55.8M | |
| Enterprise Value | 43.6M | 39.5M | 88.4M | 81.2M | 73.1M | 44.9M |
Annovis Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Annovis Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Annovis Bio's managers, analysts, and investors.Environmental | Governance | Social |
Annovis Fundamentals
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 77.87 M | ||||
| Shares Outstanding | 13.8 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 8.83 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 12.81 X | ||||
| EBITDA | (45.04 M) | ||||
| Net Income | (56.2 M) | ||||
| Cash And Equivalents | 35.97 M | ||||
| Cash Per Share | 4.41 X | ||||
| Total Debt | 17.96 M | ||||
| Debt To Equity | (0.31) % | ||||
| Current Ratio | 28.11 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (39.97 M) | ||||
| Short Ratio | 4.02 X | ||||
| Earnings Per Share | (4.22) X | ||||
| Target Price | 34.8 | ||||
| Beta | 1.7 | ||||
| Market Capitalization | 90.51 M | ||||
| Total Asset | 10.21 M | ||||
| Retained Earnings | (110.26 M) | ||||
| Working Capital | 5.93 M | ||||
| Current Asset | 986 K | ||||
| Current Liabilities | 216 K | ||||
| Net Asset | 10.21 M |
About Annovis Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Annovis Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Annovis Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Annovis Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.